Twelve of the 13 metabolites are linked to mitochondrial function, suggesting that suppression of mitochondria - the powerhouses of cells - is a fundamental characteristic of diabetic kidney disease. The findings are published in the November edition of the
"This work provides strong evidence that reduced mitochondrial function is a dominant feature of human diabetic kidney disease," said first author Kumar Sharma, MD, professor of medicine and director of the Center for Renal Translational Medicine at UC San Diego. "We found that a specific cellular pathway, AMPK-PGC1a, likely plays a key role to reduce mitochondrial function and content, which means that new therapeutic approaches that restore and increase mitochondrial function and content could ameliorate or perhaps even arrest chronic kidney disease."
Diabetic kidney disease is the leading cause of end-stage kidney disease, which is the eighth leading cause of death in the United States and a major risk factor for cardiovascular disease, the nation's leading killer. An estimated 26 million American adults have chronic kidney disease (CKD), with millions more at increased risk. These patients often require dialysis or an organ transplant.
The primary causes of CKD are high blood pressure and diabetes. Rates of both CKD and diabetes have risen dramatically in the last decade, particularly among people aged 65 and older. According to the National Kidney and Urologic Diseases Information Clearinghouse, the annual mortality rate for end-stage renal disease rose from 10,478 in 1980 to 90,118 in 2009, though it has declined somewhat in recent years.
After analyzing a total of 193 urine samples from patients with diabetes and CKD, diabetes but no CKD and healthy controls with neither condition, Sharma and colleagues quantified 94 metabolites in the samples. Thirteen metabolites were significantly different between patients with diabetes and CKD versus controls. Twelve remained significant when compared to patients with diabetes but not CKD. Twelve metabolites play a role in mitochondrial metabolism and were present in lower levels in patients with diabetes and CKD, suggesting that this major diabetic complication is at least partly the consequence of suppressed mitochondrial activity.
Sharma said measuring urine metabolites to detect and assess diabetic kidney disease is a major diagnostic step forward. "The urine metabolites can indicate the underlying function of the kidney at a biochemical and intracellular level," he said, "and are well-conserved compared to many cell-based and protein measurements. Urine metabolomics also offers an opportunity to gauge effects of new treatments which will be an advantage to guide precision medicine."
Co-authors include Bethany Karl and Maggie Diamond-Stanic, UCSD Institute of Metabolic Medicine, UCSD Center for Renal Translational Medicine and Division of Nephology-Hypertension, VA San Diego Healthcare System; Anna V. Mathew, UCSD Center for Renal Translational Medicine and Division of Nephology-Hypertension, VA San Diego Healthcare System, now at the University of Michigan; Jon A. Gangoiti, Bruce Barshop, William Nyhan, Biochemical Genetics Program and Institute of Metabolomic Medicine, UCSD; Christina L. Wassel and Minya Pu, Department of Family and Preventive Medicine, UCSD; Rintaro Saito, UCSD Institute of Metabolic Medicine, UCSD Center for Renal Translational Medicine and Division of Medical Genetics, UCSD; Shoba Sharma and Young You, UCSD Center for Renal Translational Medicine; Lin Wang, Mitochondrial and Metabolic Disease Center, UCSD; Maja T. Lindenmeyer and Clemens D. Cohen Division of Nephology, University Hospital Zurich, Switzerland; Carol Forsblom, Folkhalsan Institute of Genetics, Helsinki Finland; Wei Wu and Sanjay K. Nigam, Departments of Pediatrics and Cell and Molecular Medicine, UCSD; Joachim H. Ix, Division of Nephology-Hypertension, VA San Diego Healthcare System, UCSD Center for Renal Translational Medicine; Trey Ideker, Division of Medical Genetics, UCSD; Jeffrey B. Koop, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health; Per-Henrik Groop, Folkhalsan Institute of Genetics, Helsinki, Finland and IDI Baker Heart and Diabetes Institute, Melbourne, Australia; Loki Natarajan, UCSD Institute of Metabolomic Medicine and Department of Family and Preventive Medicine, UCSD; and Robert K. Naviaux, Mitochondrial and Metabolic Disease Center, UCSD, UCSD Institute of Metabolomic Medicine, Division of Medical Genetics, UCSD, Biochemical Genetics Program, UCSD.
Support for this research includes funding from the Juvenile Diabetes Research Foundation, the National Institute of Diabetes and Digestive and Kidney Disease, the Folkhalsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Liv och Halsa Foundation, the UCSD Christini Fund, the Wright Family Foundation, the Lennox Foundation, the Else Kroner-Fresnius Foundation, the Swiss National Center of Competence in Research and National Institutes of Health grants P41 GM103505 and P50 GM085764.